CSat Investment Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

CSat Investment Advisory’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$17K	Buy	35 +10	+40%	+$4.87K	0.01%	404
2020 Q4	$12K	Sell	25 -618	-96%	-$334K	0.01%	416
2020 Q3	$360K	Buy	643 +83	+15%	+$50.3K	0.03%	202
2020 Q2	$349K	Buy	560 +19	+4%	+$10.8K	0.04%	215
2020 Q1	$264K	Buy	541 +139	+35%	+$57.3K	0.06%	209
2019 Q4	$151K	Buy	402 +68	+20%	+$22.9K	0.04%	272
2019 Q3	$93K	Buy	334 +39	+13%	+$11.5K	0.03%	334
2019 Q2	$92K	Buy	295 +273	+1,241%	+$90.9K	0.03%	309
2019 Q1	$9K	Buy	22 +2	+10%	+$824	﹤0.01%	447
2018 Q4	$7K	Buy	20 +3	+18%	+$1.1K	﹤0.01%	460
2018 Q3	$7K	Sell	17 -7	-29%	-$2.66K	﹤0.01%	431
2018 Q2	$8K	Buy	+24	New	+$7.51K	﹤0.01%	396

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSat Investment Advisory's REGN Position: Q1 2021 in Review

CSat Investment Advisory increased its Regeneron Pharmaceuticals (REGN) stake by 40% in Q1 2021, buying an estimated $4.87K and bringing the position to 35 shares worth $17K. The position accounts for 0.01% of the portfolio, ranked #404.

CSat Investment Advisory first reported a position in REGN in Q2 2018 and has held it in 12 quarters since. The position peaked at $360K in Q3 2020. 925 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

CSat Investment Advisory held 35 shares of Regeneron Pharmaceuticals worth $17K as of Q1 2021.
CSat Investment Advisory bought 10 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $4.87K.
Regeneron Pharmaceuticals made up 0.01% of CSat Investment Advisory's portfolio in Q1 2021, its #404 holding.
CSat Investment Advisory first reported a position in Regeneron Pharmaceuticals in Q2 2018 and has held it in 12 quarters since.
CSat Investment Advisory's Regeneron Pharmaceuticals position peaked at $360K in Q3 2020.
925 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on CSat Investment Advisory's 13F filing for Q1 2021, filed 13 May 2021.